@article{2f2f523c79344c0bbc38d8942da80a2d,
title = "Plasma circulating miR-23~27~24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes",
abstract = "Aims/hypothesis: We aimed to analyse the association between plasma circulating microRNAs (miRNAs) and the immunometabolic profile in children with type 1 diabetes and to identify a composite signature of miRNAs/immunometabolic factors able to predict type 1 diabetes progression. Methods: Plasma samples were obtained from children at diagnosis of type 1 diabetes (n = 88) and at 12 (n = 32) and 24 (n = 30) months after disease onset and from healthy control children with similar sex and age distribution (n = 47). We quantified 60 robustly expressed plasma circulating miRNAs by quantitative RT-PCR and nine plasma immunometabolic factors with a recognised role at the interface of metabolic and immune alterations in type 1 diabetes. Based on fasting C-peptide loss over time, children with type 1 diabetes were stratified into the following groups: those who had lost >90% of C-peptide compared with diagnosis level; those who had lost ",
keywords = "Biomarkers, Cardiovascular risk, Diabetic complications, Immunometabolism, Insulin secretion, microRNA, Osteoprotegerin, biological marker, C peptide, circulating microRNA, cytokine receptor, hormone receptor, insulin, leptin, lymphocyte antigen, microRNA 23, microRNA 23a 3p, microRNA 23b 3p, microRNA 24, microRNA 24 3p, microRNA 27, microRNA 27a 3p, microRNA 27b 3p, monocyte chemotactic protein 1, myeloperoxidase, osteoprotegerin, resistin, soluble cd40 ligand, soluble intercellular adhesion molecule 1, soluble leptin receptor, soluble tumor necrosis factor receptor, unclassified drug, age distribution, Article, artificial neural network, child, clinical evaluation, cohort analysis, comparative study, controlled study, correlation coefficient, disease association, disease duration, disease exacerbation, fasting, female, gene expression level, gene expression regulation, human, immune dysregulation, immunomodulation, immunopathology, independent variable, inflammation, insulin dependent diabetes mellitus, insulin release, insulin treatment, major clinical study, male, metabolic disorder, pediatric patient, plasma, predictive value, priority journal, prognosis, real time polymerase chain reaction, retrospective study, school child, sex ratio, signal transduction, upregulation, validation study",
author = "S. Garavelli and S. Bruzzaniti and E. Tagliabue and {Di Silvestre}, D. and F. Prattichizzo and E. Mozzillo and V. Fattorusso and {La Sala}, L. and A. Ceriello and A.A. Puca and P. Mauri and R. Strollo and M. Marigliano and C. Maffeis and A. Petrelli and E. Bosi and A. Franzese and M. Galgani and G. Matarese and {de Candia}, P.",
note = "Cited By :3 Export Date: 11 March 2021 CODEN: DBTGA Correspondence Address: de Candia, P.; IRCCS MultiMedica, via G. Fantoli 16/15, Italy; email: paola.decandia@multimedica.it Correspondence Address: Galgani, M.; Institute for Endocrinology and Experimental Oncology {\textquoteleft}G. Salvatore{\textquoteright}, via Pansini 5, Italy; email: mario.galgani@unina.it Correspondence Address: Matarese, G.; Institute for Endocrinology and Experimental Oncology {\textquoteleft}G. Salvatore{\textquoteright}, via Pansini 5, Italy; email: giuseppe.matarese@unina.it Chemicals/CAS: C peptide, 59112-80-0; insulin, 9004-10-8; myeloperoxidase; osteoprotegerin, 205944-50-9 Funding details: 2016/R/18, 2017 K55HLC 001, 2018/S/5, 3-APF-2019-744-A-N, PP-1804-30725 Funding details: National Multiple Sclerosis Society Funding details: Fondazione Italiana Sclerosi Multipla, FISM, 2-SRA-2018-479-S-B, 2016/R/10, 2018/R/4 Funding details: Juvenile Diabetes Research Foundation United States of America, JDRF, 1-SRA-2018-477-S-B Funding details: Universit{\`a} degli Studi di Salerno, UNISA Funding text 1: PdC gratefully acknowledges funding from the JDRF for this research (JDRF no. 1-SRA-2018-477-S-B). PdC is also funded by Fondazione Italiana Sclerosi Multipla (FISM no. 2016/R/10 and n. 2018/R/4). This work was also supported by JDRF grant no. 2-SRA-2018-479-S-B to MG and by funds from the European Foundation for the Study of Diabetes/Juvenile Diabetes Research Foundation/Lilly program 2015 to GM and program 2016 to MG. MG was also funded by the National Multiple Sclerosis Society (NMSS no. PP-1804-30725) and GM was also funded by FISM (grant 2016/R/18 and 2018/S/5) and Progetti di Rilevante Interesse Nazionale (PRIN) 2017 K55HLC 001. AP is supported by JDRF grant no. 3-APF-2019-744-A-N. This work has also been supported by Italian Ministry of Health Ricerca Corrente - IRCCS MultiMedica. Funding text 2: We acknowledge A. Stabilini (San Raffaele Diabetes Research Institute, Milan, Italy) who performed sample collection, processing, storage and recovery and R. Bonfanti (Paediatric Department, Ospedale San Raffaele, Milan, Italy) who was involved in the enrolment of participants from validation cohort 1. We would also like to thank A. Perfetti and F. Martelli (IRCCS Policlinico San Donato, Milan, Italy) for sharing the heparinase protocol. Schematic figures (including those in the ESM) were created with images adapted from Servier Medical Art by Servier (http://www.servier.fr/servier-medical-art ). Finally, we express gratitude to A. Pontiroli (Health Science Department, University of Milan, Italy) and S. Scarpetta (Physics Department, University of Salerno, Italy) for useful discussions and to A. Torri for her precious contribution in setting up the plasmatic miRNA quantification. The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.",
year = "2020",
doi = "10.1007/s00125-020-05237-x",
language = "English",
volume = "63",
pages = "2699--2712",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "12",
}